Drug Database
Back to search

France· FR:67134227

PEGASYS 180 microgrammes, solution injectable en seringue préremplie

A peginterferon alfa-2a product containing peginterféron alfa-2a, registered in France by PHARMAAND (AUTRICHE), on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC L03AB11

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedPEGASYS 180 microgrammes, solution in…ATCL03AB11REGISTER NO.FR:67134227PACKS LISTED2CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about peginterféron alfa-2aAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Peginterferon alfa-2a is registered in 14 of 19 countries.

Countries holding a registration under ATC L03AB11 (peginterferon alfa-2a), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose
Search peginterferon alfa-2a products by name

Peginterferon alfa-2a · ATC L03AB11

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
PEGINTERFÉRON ALFA-2A
Manufacturer
PHARMAAND (AUTRICHE)
Country
France (FR)
ATC code
L03AB11
ATC class
Peginterferon alfa-2a
Defined daily dose
26 mcg, P
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 2

2 priced
  • cip13
    3400935996060
    1 seringue(s) préremplie(s) en verre de 0,5 ml avec aiguille(s)
    EUR 220.59
  • cip13
    3400935996121
    4 seringue(s) préremplie(s) en verre de 0,5 ml avec aiguille(s)
    EUR 855.89

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

201 interactions on record for peginterferon alfa-2a.

Graded by severity as the source publishes them — 35 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check peginterferon alfa-2a against other medicinesHow interaction checks work

Peginterferon alfa-2a · interactions on record

201 records

  • 35 severe
  • 163 moderate
  • 3 minor

Most severe, free to view

  • EltrombopagB02BX05severe
  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • TelbivudineJ05AF11severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Peginterferon alfa-2a in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All peginterferon alfa-2a products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Pegasys
  • Liechtenstein · Pegasys
  • Norway · Pegasys

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c49d3194-4123-44fa-903d-1f385f884dfb
GET /v1/drugs/c49d3194-4123-44fa-903d-1f385f884dfb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "67134227",
  "date_amm": "2002-06-20",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/02/221",
  "substance": "PEGINTERFÉRON ALFA-2A",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about peginterferon alfa-2a.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console